The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Lots of stars are slimming down, igniting a Hollywood trend that raises concerns about the return of dangerous beauty standards.

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk ( NVO) announced a new cash-pay option for its blockbuster weight-loss drug Wegovy, offering a monthly dose at $499 and home delivery. The move follows competitor Eli Lilly ( LLY ), which ...

Whoopi Goldberg has stunned in her latest looks showing off her 100+ pound weight loss after taking popular weight loss drug ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...